Calcineurin inhibitors revisited: A new paradigm for COVID-19?

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can cause mild, moderate or severe disease (COVID-19). In severe disease, there is hyperinflammation causing severe symptoms. Severe COVID-19 is an immunological phenomenon, rather than a direct viral damage disease. Therapies for COVID-19 are all investigational therapies. In case of severe disease, treatment with a calcineurin inhibitor could be promising. In this article we explain the mechanisms of calcineurin inhibitor treatment for COVID-19, based on experiences seen in solid organ transplant recipients who suffered from COVID-19. Copyright © 2020 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. All rights reserved.

Citation

René Hage, Carolin Steinack, Macé M Schuurmans. Calcineurin inhibitors revisited: A new paradigm for COVID-19? The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases. 2020 Jul - Aug;24(4):365-367

Mesh Tags

Substances

PMID: 32603679

search → result